Item 2.02 Results of Operations and Financial Condition.

On January 5, 2023, USANA Health Sciences, Inc. (the "Company") issued a press release providing information regarding its financial and operational results for the full fiscal year ended December 31, 2022, and guidance with respect to the Company's currently expected financial results for the fiscal year ending December 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1.

The information, including Exhibit 99.1, in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

Item 7.01 Regulation FD Disclosure

On January 5, 2023, the Company issued a press release announcing preliminary financial results for the fiscal year ended December 31, 2022 along with initial guidance for fiscal year 2023. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.



           (d) Exhibits
Exhibit No.     Description
99.1            Press release issued by USANA Health Sciences, Inc. dated January 5,
                2023 (furnished herewith).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses